With the introduction of new drugs approved for pre-exposure prophylaxis (PrEP) and generic options becoming available, the HIV PrEP landscape is rapidly changing. NASTAD’s FAQ provides current information on the introduction of PrEP generics, potential coverage changes related to the changing PrEP drug market, and the impact on PrEP access.
Julia Zigman is a Program Analyst on the NACCHO HIV, STI, & Viral Hepatitis team. Julia focuses primarily on NACCHO’s Ending the HIV Epidemic portfolio and is a lead staff member for the HIV, STI, and Viral Hepatitis Workgroup. Learn more about these programs here.
